# A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC

> **NCT05756972** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Biotheus Inc.** · enrollment: 64 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** PM8002
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT05756972
- **Lead sponsor:** Biotheus Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-26
- **Primary completion:** 2024-09-13
- **Final completion:** 2025-12
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05756972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05756972, "A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05756972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*